GleamWall
中文EN

JUNS JUPITER NEUROSCIENCES, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1679628 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-86.1%
TTM EPS YoY71.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-673.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets171.6%
Debt / equity—
Current ratio0.49x
Interest coverage-39.17x

Cash quality & payout

Operating cash flow / net income0.62x
Accruals ratio-253.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$21,796$0
Cost of revenue$4,231—
Gross profit$17,565—
R&D expense$2.09M$492,660
SG&A expense$6.84M$2.60M
Operating income-$8.91M-$3.09M
Interest expense$66,020$248,366
Net income-$8.64M-$2.44M
EPS (basic)-0.25-0.08
EPS (diluted)-0.25-0.08
Weighted avg. shares (diluted)34.63M28.78M
Balance sheet
Cash & equivalents$3.79M$3.77M
Receivables$2,637—
Inventory$159,790—
Current assets$4.82M$4.65M
Total assets$5.56M$6.20M
Current liabilities$7.40M$2.01M
Total liabilities$7.40M$2.03M
Shareholders' equity-$1.83M$4.17M
Shares outstanding459,28633.10M
Cash flow statement
Operating cash flow-$5.41M-$3.91M
Financing cash flow$5.43M$7.65M
Stock-based compensation$2.42M$1.84M

Free plan shows the latest 2 periods; Pro shows all 3 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.